20 December 2019 - Sunovion Pharmaceuticals today announced that the U.S. FDA has accepted its new drug application for apomorphine sublingual film (APL-130277) to treat motor fluctuations (OFF episodes) experienced by people living with Parkinson’s disease, which was resubmitted on 21 November 2019. 

The expected action date by the FDA under the Prescription Drug User Fee Act is 21 May 2020.

Read Sunovion Pharmaceuticals press release